View Post

Sanofi’s, AstraZeneca’s and Radius’ oral SERDs could establish clinical worth in ER+ breast cancer by showing similar efficacy to Faslodex, experts say

In Clinical Studies News by Barbara Jacoby

By: Manasi Vaidyacl From: clinicaltrialsarena.com Oral SERDs by AstraZeneca, Sanofi and Radius Health can demonstrate clinical value by being comparable, rather than superior to, AstraZeneca’s Faslodex (fulvestrant) or generic aromatase inhibitors in oestrogen receptor positive (ER+) HER2-negative breast cancer, said experts. Oral SERDs by AstraZeneca, Sanofi and Radius Health can demonstrate clinical value by being comparable, rather than superior to, …

View Post

Maverick Therapeutics to Use Inivata’s Liquid Biopsy Assay in Phase I/II Clinical Study

In Clinical Studies News by Barbara Jacoby

By: Staff Reporter 115 From: precisiononcologynews.com Inivata said on Thursday that it has partnered with Maverick Therapeutics to use Inivata’s Radar (Residual Disease and Recurrence) assay to detect and monitor residual disease and recurrence in patients enrolled in Maverick’s Phase I/II clinical study for its MVC-101 drug candidate. As part of the study, the team will use Radar to monitor circulating tumor …

View Post

Neoadjuvant Durvalumab Regimen Improves Responses in Triple-Negative Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Danielle Ternyila From: targetedonc.com In an interview with Targeted Oncology, Lajos Pusztai, MD, DPhil, discussed the findings from the phase I/II clinical trial of durvalumab in combination with concurrent nab-paclitaxel and doxorubicin plus cyclophosphamide in the neoadjuvant setting for patients with triple-negative breast cancer. A phase I/II study demonstrated that the addition of durvalumab in the neoadjuvant setting to …

View Post

Phase I/II Clinical Study of ONC201 Begins in Japan

In Clinical Studies News by Barbara Jacoby

Oncoceutics, Inc., announced that it was informed by its Japanese licensee, Ohara Pharmaceutical Co., Ltd., of the initiation of a Phase I/II clinical study of OP-10 (the Japanese name for ONC201) in Japan and the administration of the drug to the first patient. ONC201 is a novel small molecule with a unique mechanism of action that has demonstrated anti-cancer activity …

View Post

Amgen’s drug targeting ‘undruggable’ protein shines at lung cancer conference

In Clinical Studies News by Barbara Jacoby

By: Alaric DeArment From: medcitynews.com Amgen presented data for the KRAS G12C inhibitor AMG 510 at the World Conference on Lung Cancer in Barcelona, showing a 54 percent response rate among patients receiving the pivotal study dose. A drug in development for a protein target once thought unreachable by pharmaceutical means has new data showing its potential efficacy in lung …

View Post

Clinical trial underscores promise of immunotherapy, in combination with second drug, for ovarian cancer

In Clinical Studies News by Barbara Jacoby

From: dana-farber.org A combination of an immunotherapy drug and a DNA repair-blocking agent can be significantly more effective than either drug alone in women with hard-to-treat ovarian cancer, a phase I/II clinical trial led by Dana-Farber Cancer Institute researchers indicates. The trial, known as TOPACIO/Keynote-162, offers compelling evidence that immunotherapies, which rarely have an impact against ovarian cancer as single …

View Post

Novel Agent Granted Orphan Drug Designation for T-Cell Prolymphocytic Leukemia

In Clinical Studies News by Barbara Jacoby

By: Audrey Sternberg From: targetedonc.com Investigational agent tinostamustine (EDO-S101), a first-in-class alkylating deacetylase inhibiting molecule, has been granted orphan drug designation by the FDA for the treatment of patients with T-cell prolymphocytic leukemia (T-PLL).1 “This orphan drug designation represents an important step…for patients suffering from T-PLL who do not currently have sufficient treatment options,” said Richard Fanelli, PhD, head of …